Member Info for EmeraldCarrots

Time we got other news, and there is a big list. Any of which should propel the sp higher. So many iron's in the fire other news can't be far off............ at all. Exciting times!

Additional:-

Fevertreeman.

"After 10 years of hype, misinformation, failed initiatives, work that went nowhere, repeated revenue misses, endless equity raises, & woeful arrogance, Newland is close to running out of road with serious investors. He now needs to deliver proper commercial results that match his endless puffery. After £100m and counting from s/holders, that he has turned into a pitiful £2.9m of revenues, he has no more lives left.".

=====================================

And with the tie up with Illumina, who's market cap is $21 Billion it looks as if he will. Plus, don't forget the Contracts with Eisai ($15 billion market cap) and Astrazeneca ($200 billion market cap). Illumina and Angle have worked together to enable the dual analysis of both CtDna and circulating tumour cells (CTC’S) from the same tube of blood. The first one is dual analysis for lung cancer. Obviously, similar assay panels are being worked on for other cancers. These are now jointly being promoted by Illumina (clients 9,500), and Angle (clients about 300).

This is why the sp has substantially increased this year.

I should add Angle's Parsortix machine is needed to catch the alive and intact CTC's before using the assay panels to test. The Parsortix research model is about $70,000, the medical use one about $80,000. The one time use filter cassettes about $300 each. This should generate substantial cash. The we have the prospect of the services side providing CTC analysis before, during and after cancer drug trials. Possibly 10's of millions more.

- It's a buy!

All IMHO.

Fevertreeman.

"After 10 years of hype, misinformation, failed initiatives, work that went nowhere, repeated revenue misses, endless equity raises, & woeful arrogance, Newland is close to running out of road with serious investors. He now needs to deliver proper commercial results that match his endless puffery. After £100m and counting from s/holders, that he has turned into a pitiful £2.9m of revenues, he has no more lives left.".

=====================================

And with the tie up with Illumina, who's market cap is $21 Billion it looks as if he will. Plus, don't forget the Contracts with Eisai ($15 billion market cap) and Astrazeneca ($200 billion market cap). Illumina and Angle have worked together to enable the dual analysis of both CtDna and circulating tumour cells (CTC’S) from the same tube of blood. The first one is dual analysis for lung cancer. Obviously, similar assay panels are being worked on for other cancers. These are now jointly being promoted by Illumina (clients 9,500), and Angle (clients about 300).

This is why the sp has substantially increased this year.

All IMHO.

Tomorrow.

Https://us02web.zoom.us/webinar/register/WN_9UPdY_OjTHavuoH53W2y7A#/registration

TwoGood2Die, researcher1, Bankruptstock, Moab and GordonGecko123 are absolutely delighted. LOL!

Tick up.

Excellent.

This is difficult for the Directors having thought about it again recently. If they bought @ sub 10 a while back they could have been accused of cashing in when others bought way above £1.00 a few years back. The shares they have were bought way above the current levels so they are down shedloads. Some in the 20's and some on the 80's if memory serves. Difficult.

Page? This is why I post more than some like. It's called spreading the word. This page is a good place to find shares that are in the news too.........

https://www.lse.co.uk/share-chat.html

Like my posts use the filter. How rude!

Liamcossie.

"You think Illumina would be working some sort of arrangement, deal with machines now?

Rather than push angle and the presentation then when the clients come asking for the equipment, follow up to the presentation of what happens next as in how does this progress from here.".

============================

Good question. I would guess that Illumina's existing 9,500 clients all around the World will be made aware the new dual analysis is available for lung cancer for starters. Clearly Illumina panels for other cancers will be following on in due course. I don't know if Angle offer this as a service yet, or whether the client would need to buy a Parsortix machine to sit alongside the Illumina kit to enable the dual analysis. I mean if Angle offered this as a service, I think they might get swamped with orders. Angle are quite a small Company don't forget. As far as working some sort of arrangement, deal with machines now goes I'm not sure. Illumina win by their kit being used more/more demand and it's their assay panel too. More to come no doubt.

Interesting tomes indeed for the board at Angle Plc!!!!

All IMHO.

Competitors. The penny still has not dropped. The RNS will be transformational for Angle Plc IMHO. You will see.

https://www.lse.co.uk/rns/AGL/analysis-of-ctc-dna-and-ctdna-using-illumina-assay-mqynkijrkyza9ga.html

All IMHO.

Machines as possible. The basic research version is about $70,000. The clinical use model about $80,000. The one time use cassettes about $300 each. The dual analysis (CtDna AND Circulating tumour cell analysis (CTC's)) can only be done using Angle's Parsortix machine (to catch the live and intact CTC's). The dual analysis gives the prospect of finding more biomarkers that can be targeted by modern cancer drugs. So, this new Illumina assay and the ones that will no doubt follow will help sell more of the machines. I suspect a lot more!!

https://www.lse.co.uk/rns/AGL/analysis-of-ctc-dna-and-ctdna-using-illumina-assay-mqynkijrkyza9ga.html

All IMHO.

Can't do the dual analysis without Angle's Parsortix machine. Getting left behind in the liquid biopsy race is a real possibility.

All IMHO.

The below RNS was dated 15th July 2024, over 6 months ago............

https://www.lse.co.uk/rns/GDR/breakthrough-device-designation-from-the-us-fda-2zclfstav7guqaq.html

Mutations in 61 clinically relevant genes"!

The first Illumina assay panel to be integrated into the new Angle/Illumina dual analysis system is the Illumina 79 gene lung cancer one. Obviously Angle and Illumina will be working to add more Illumina panels to the offering, Breast cancer, liver cancer etc. That begs the question what about the exclusive agreement for "NuProbe USA, Inc." DNA NGS panel. The RNS of 23rd Sept 2024 refers to it. Says this analysis panel "enables highly sensitive and specific detection of over ***6,500 DNA mutations in 61 clinically relevant genes*** and been found to be the highest performing multi-gene assay of those evaluated by ANGLE.".

https://www.lse.co.uk/rns/AGL/exclusive-agreement-for-dna-ngs-panel-kjf10rvhdvv0bum.html

https://www.lse.co.uk/rns/AGL/analysis-of-ctc-dna-and-ctdna-using-illumina-assay-mqynkijrkyza9ga.html

This was/is a cancer breakthrough by Angle Plc made possible by their Parsortix machine.

The dual analysis is going to get adopted as std in the industry IMHO.

All IMHO.

Tie up With Illumina, the biggest DNA analysis Co. in the USA, and 2nd biggest in the entire World? 21 BILLION MARKET CAP....... Illumina ALREADY work closerly with the UK's NHS, *****providing lab services for the hospitals**** in the whole UK. The sp won't Be this cheap for much longer, believe me. 16.5p to buy. 40p in weeks.

All IMHO.

Tie up With Illumina, the biggest DNA analysis Co. in the USA, and 2nd biggest in the entire World? 21 BILLION MARKET CAP....... Illumina ALREADY work closerly with the UK's NHS, *****providing lab services for the hospitals**** in the whole UK. The sp won't Be this cheap for much longer, believe me.

All IMHO.

Tick up again.

Fas as the sp goes. Illumina Inc. market cap ****TWENTY ONE BILLION DOLLARS*****.............................